Join to View Full Profile
500 UNIVERSITY DRHershey, PA 17033
Phone+1 717-531-0003
Dr. Annageldiyev is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Charyguly Annageldiyev is an oncology specialist based in Hershey, PA, with a subspecialty in hematologic oncology. He completed his education and training at Penn State Milton S. Hershey Medical Center, including a fellowship in hematology and medical oncology and a residency in internal medicine. As a hematology/oncology fellow, he currently works at Penn State Milton S. Hershey Medical Center and has experience with conditions such as lung cancer and various hematological disorders. Dr. Annageldiyev has authored several publications focused on leukemia and has received multiple awards, including the Fellow of the Year from Penn State University in 2023.
Education & Training
Penn State Milton S Hershey Medical CenterFellowship, Hematology and Medical Oncology, 2022 - 2026- Penn State Milton S Hershey Medical CenterResidency, Internal Medicine, 2020 - 2022
- Penn State Milton S Hershey Medical CenterPost-Doctoral Fellowship, Hematology and Medical Oncology, 2016 - 2020
OtherClass of 2015, MD, Meram School of Medicine
Certifications & Licensure
PA State Medical License 2020 - 2024
American Board of Internal Medicine Internal Medicine
Awards, Honors, & Recognition
- Fellow of the year Penn State University, Department of Medicine, 2023
- Bradley and Bond Travel Award Penn State College of Medicine, 2019
- Best Research Award Penn State Cancer Institute, 2018
Publications & Presentations
PubMed
- Cytotoxic lymphocytes induced by engineered human dendritic cells mediate potent anti-leukemia activity.Chenchen Zhao, Bei Jia, Yixing Jiang, Hiroko Shike, Charyguly Annageldiyev
Cancer Immunology, Immunotherapy. 2025-02-25 - 2 citationsActivation of GPR44 decreases severity of myeloid leukemia via specific targeting of leukemia initiating stem cells.Fenghua Qian, Shaneice K Nettleford, Jiayan Zhou, Brooke E Arner, Molly A Hall
Cell Reports. 2023-07-25 - 3 citationsCD26PD-1CD8 T cells are terminally exhausted and associated with leukemia progression in acute myeloid leukemia.Huarong Zhou, Bei Jia, Charyguly Annageldiyev, Kentaro Minagawa, Chenchen Zhao
Frontiers in Immunology. 2023-01-01
Journal Articles
- A Xenograft Mouse Model to Assess Efficacy of Therapeutic Agents for Human Acute LeukemiaChandrika Gowda*, Charyguly Annageldiyev*, Pavan Kumar Dhanyamraju, Morgann Klink, Sinisa Dovat, Mark Kester, Thomas P. Loughran, Jr, David Claxton, Arati Sharma, JOVE, 3/1/2020
Books/Book Chapters
Press Mentions
"Don't be like patient 31": How a person plunged South Korea deep into the crisisMay 5th, 2020
Research History
- Role of Casein Kinase 2 (CK2) in Leukemia2024 - Present
- Developing novel therapeutics for AML2020 - Present
- Developing Patient-Derived Xenograft (PDX) models in Acute Leukemia2018 - Present
- Developing novel therapeutics against Cancer stem cells2016 - Present
- Targeting Sphingolipid Metabolism for treatment of AML2016 - 2020
Professional Memberships
- Member
- Member
- Member
External Links
- Google Scholarhttp://scholar.google.com/citations?user=R1Q4bTIAAAAJ&hl=en&oi=ao
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
